TL1A Induces TCR independent IL-6 and TNF-α production and growth of PLZF+ leukocytes

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Reichwald, Kirsten ^a   Jørgensen, Tina Z ^a   Tougaard, Peter ^a   Skov, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE LIGAND 1A; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; MONOCYTE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INDUCTION;

ANTIGENS, CD14; CELL PROLIFERATION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTRACELLULAR SPACE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; STAINING AND LABELING; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896972682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085793     Document Type: Article

References (58)

1. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, et al. (2002) TL1A is a TNFlike ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492. S1074761302002832 [pii].
2. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, et al. (2008) Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 129: 249-255. S1521-6616(08)00728-6 [pii];10.1016/j.clim.2008.07.014 [doi].
3. Cassatella MA, Pereira-da-Silva G, Tinazzi I, Facchetti F, Scapini P, et al. (2007) Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178: 7325-7333. 178/11/7325 [pii].
4. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, et al. (2009) Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 183: 5350-5357. jimmunol. 0802645 [pii];10.4049/jimmunol.0802645 [doi].
5. Bamias G, Evangelou K, Vergou T, Tsimaratou K, Kaltsa G, et al. (2011) Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol 20: 725-731. 10.1111/j.1600-0625.2011.01304.x [doi].
6. Bamias G, Kaltsa G, Siakavellas SI, Gizis M, Margantinis G, et al. (2012) Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis 44: 30-36. S1590-8658(11)00343-4 [pii];10.1016/j.dld.2011.09.002 [doi].
7. Bamias G, Martin C, III, Marini M, Hoang S, Mishina M, et al. (2003) Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171: 4868-4874. (Pubitemid 37310609)
8. Konsta M, Bamias G, Tektonidou MG, Christopoulos P, Iliopoulos A, et al. (2012) Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology (Oxford). kes316 [pii];10.1093/rheumatology/kes316 [doi].
9. Bayry J (2010) Immunology: TL1A in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 6: 67-68. nrrheum.2009.263 [pii];10.1038/nrrheum. 2009.263 [doi].
10. Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, et al. (2008) TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 205: 1049-1062. jem.20071364 [pii];10.1084/jem.20071364 [doi].
11. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL (2011) Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int. 10.1007/s00296-011-1984-x [doi].
12. Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, et al. (2011) Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J 25: 409-419. fj.10-166843 [pii];10.1096/fj.10-166843 [doi].
13. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, et al. (2008) The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 205: 2457-2464. jem.20072378 [pii];10.1084/jem.20072378 [doi].
14. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, et al. (2008) The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29: 79-89. S1074-7613(08)00269-0 [pii];10.1016/j.immuni.2008. 04.021 [doi].
15. Fang L, Adkins B, Deyev V, Podack ER (2008) Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 205: 1037-1048. jem.20072528 [pii];10.1084/jem.20072528 [doi].
16. Twohig JP, Marsden M, Cuff SM, Ferdinand JR, Gallimore AM, et al. (2012) The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. FASEB J 26: 3575-3586. fj.11-200618 [pii];10.1096/fj.11-200618 [doi].
17. Buchan SL, Taraban VY, Slebioda TJ, James S, Cunningham AF, et al. (2012) Death receptor 3 is essential for generating optimal protective CD4(+) T-cell immunity against Salmonella. Eur J Immunol 42: 580-588. 10.1002/eji.201041950 [doi].
18. Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89. S1359-6101(11)00005-0 [pii];10.1016/j.cytogfr.2011.02.003 [doi].
19. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238. nature04753 [pii];10.1038/nature04753 [doi].
20. Emery P, Keystone E, Tony HP, Cantagrel A, van VR, et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523. ard.2008.092932 [pii];10.1136/ard.2008.092932 [doi].
21. Goodman WA, Young AB, McCormick TS, Cooper KD, Levine AD (2011) Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol 186: 3336-3345. jimmunol.1001455 [pii];10.4049/jimmunol.1001455 [doi].
22. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, et al. (2009) IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183: 3170-3176. jimmunol.0803721 [pii];10.4049/jimmunol.0803721 [doi].
23. Papadakis KA, Prehn JL, Landers C, Han Q, Luo X, et al. (2004) TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 172: 7002-7007. (Pubitemid 38669141)
24. Papadakis KA, Zhu D, Prehn JL, Landers C, Avanesyan A, et al. (2005) Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFNgamma production by peripheral blood and mucosal CCR9 + T lymphocytes. J Immunol 174: 4985-4990. 174/8/4985 [pii].
25. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, et al. (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162: 4511-4520. (Pubitemid 29314849)
26. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, et al. (2012) Cytokine activation induces human memory-like NK cells. Blood 120: 4751-4760. blood-2012-04-419283 [pii];10.1182/blood-2012-04-419283 [doi].
27. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, et al. (2010) Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood 116: 575-583. blood-2009-08-240325 [pii];10.1182/blood-2009-08-240325 [doi].
28. Harris KM (2011) Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol 90: 727-734. jlb.0311132 [pii];10.1189/jlb.0311132 [doi].
29. Ben AM, Belhadj HN, Moes N, Buyse S, Abdeladhim M, et al. (2009) IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182: 6763-6770. 182/11/6763 [pii];10.4049/jimmunol.0801792 [doi].
30. Littman DR, Rudensky AY (2010) Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140: 845-858. S0092-8674(10)00174-1 [pii];10.1016/j.cell.2010.02.021 [doi].
31. Rodrigues L, Nandakumar S, Bonorino C, Rouse BT, Kumaraguru U (2009) IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response. Mol Immunol 46: 1494-1504. S0161-5890(08)00808-0 [pii];10.1016/j.molimm.2008.12.033 [doi].
32. Skov S, Bonyhadi M, Odum N, Ledbetter JA (2000) IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells. J Immunol 164: 3500-3505.ji- v164n7p3500 [pii].
33. Correia MP, Costa AV, Uhrberg M, Cardoso EM, Arosa FA (2011) IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 216: 604-612. S0171-2985(10)00179-8 [pii];10.1016/j.imbio.2010.09.012 [doi].
34. Gagnon J, Ramanathan S, Leblanc C, Cloutier A, McDonald PP, et al. (2008) IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J Immunol 180: 7958-7968. 180/12/7958 [pii].
35. Bezbradica JS, Medzhitov R (2009) Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 10: 333-339. ni.1713 [pii];10.1038/ni.1713 [doi].
36. Guo L, Junttila IS, Paul WE (2012) Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol 33: 598-606. S1471-4906(12)00128-7 [pii];10.1016/j.it.2012.07.006 [doi].
37. Spits H, Di Santo JP (2011) The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 12: 21-27. ni.1962 [pii];10.1038/ni.1962 [doi].
38. Tough DF, Borrow P, Sprent J (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950. (Pubitemid 26234507)
39. Boyman O (2010) Bystander activation of CD4+ T cells. Eur J Immunol 40: 936-939. 10.1002/eji.201040466 [doi].
40. Kotaja N, Sassone-Corsi P (2004) Plzf pushes stem cells. Nat Genet 36: 551-553. 10.1038/ng0604-551 [doi];ng0604-551 [pii].
41. Alonzo ES, Sant'Angelo DB (2011) Development of PLZF-expressing innate T cells. Curr Opin Immunol 23: 220-227. S0952-7915(10)00231-1 [pii];10.1016/j.coi. 2010.12.016 [doi].
42. Quah BJ, Warren HS, Parish CR (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2: 2049-2056. nprot.2007.296 [pii];10.1038/nprot.2007.296 [doi].
43. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511. 10.1038/nri1391 [doi];nri1391 [pii].
44. Savage AK, Constantinides MG, Han J, Picard D, Martin E, et al. (2008) The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29: 391-403. S1074-7613(08)00337-3 [pii];10.1016/j.immuni. 2008.07.011 [doi].
45. Kreslavsky T, Savage AK, Hobbs R, Gounari F, Bronson R, et al. (2009) TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A 106: 12453-12458. 0903895106 [pii];10.1073/pnas.0903895106 [doi].
46. Lee YJ, Jeon YK, Kang BH, Chung DH, Park CG, et al. (2010) Generation of PLZF+ CD4+ T cells via MHC class II-dependent thymocyte-thymocyte interaction is a physiological process in humans. J Exp Med 207: 237-246. jem.20091519 [pii];10.1084/jem.20091519 [doi].
47. Weinreich MA, Odumade OA, Jameson SC, Hogquist KA (2010) T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells. Nat Immunol 11: 709-716. ni.1898 [pii];10.1038/ni.1898 [doi].
48. Kovalovsky D, Alonzo ES, Uche OU, Eidson M, Nichols KE, et al. (2010) PLZF induces the spontaneous acquisition of memory/effector functions in T cells independently of NKT cell-related signals. J Immunol 184: 6746-6755. jimmunol.1000776 [pii];10.4049/jimmunol.1000776 [doi].
49. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS (2004) CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 50: 2775-2785. 10.1002/art.20499 [doi]. (Pubitemid 39209514)
50. Buckner JH (2010) Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 10: 849-859. nri2889 [pii];10.1038/nri2889 [doi].
51. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15: 43-58. 10.1096/fj.99-1003rev [doi];15/1/43 [pii].
52. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/ sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11: 613-624. 10.1517/14728222.11.5.613 [doi]. (Pubitemid 46730080)
53. Assier E, Boissier MC, Dayer JM (2010) Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 77: 532-536. S1297-319X(10)00198-3 [pii];10.1016/j.jbspin.2010.07.007 [doi].
54. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, et al. (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889-894. ard.2005.043166 [pii];10.1136/ard.2005.043166 [doi].
55. Fleming JO (2013) Helminth therapy and multiple sclerosis. Int J Parasitol 43: 259-274. S0020-7519(12)00315-3 [pii];10.1016/j.ijpara.2012.10.025 [doi].
56. Itsumi M, Yoshikai Y, Yamada H (2009) IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells. Eur J Immunol 39: 1784-1793. 10.1002/eji.200839106 [doi].
57. Niedbala W, Wei X, Liew FY (2002) IL-15 induces type 1 and type 2 CD4+ and CD8+ T cells proliferation but is unable to drive cytokine production in the absence of TCR activation or IL-12/IL-4 stimulation in vitro. Eur J Immunol 32: 341-347. 10.1002/1521-4141(200202)32: 2, 341:: AID-IMMU341.3.0. CO;2-X [pii];10.1002/1521-4141(200202)32:2& #60;341::AIDIMMU341& # 62;3.0.CO;2-X [doi].
58. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, et al. (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193: 219-231. (Pubitemid 32524453)